<DOC>
	<DOCNO>NCT01057160</DOCNO>
	<brief_summary>This multicentre , open label , prospective , randomize , two-attack study active comparator patient report inadequate response analgesic and/or triptans examine efficacy Rizatriptan 10 mg RPD group patient .</brief_summary>
	<brief_title>Rizatriptan 10 MG RPD Treatment Acute Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Patient 's signature inform consent document [ patient give ample time read ( read ) consent form , ask question may regard trial clear understanding trial procedure involve prior sign consent form ] . Have clinical diagnosis migraine without aura accord IHS criterion least one year prior enrollment . At screen least two migraine attack per month ten last three month prior inclusion . At screen stable dose prophylactic medication ( include prophylactic treatment ) least two month change prophylactic medication active trial period . Contraindication triptans Rizatriptan accord medical information sheet . Patient history clinical evidence ischemic heart disease ( e.g. , angina pectoris type , history myocardial infarction document silent ischemia ) symptoms findings consistent ischemic heart disease , coronary artery vasospasm ( include Prinzmetal 's variant angina ) , significant underlie cardiovascular disease . Patient uncontrolled hypertension . Patient either demonstrate hypersensitivity experience serious adverse event response Rizatriptan inactive ingredient . History treatment failure least one triptan treatment acute migraine attack . Any headache , except tension type headache 5 less day month within three month prior screen . A history drug induce headache , medication overuse headache addiction . Any history allergic hypersensitivity poor tolerance component preparation use trial . Females childbearing potential use reliable mean birth control , pregnant lactating female expected/ plan pregnancy . Participation ( plan current ) investigational drug device trial within previous 30 day prior screen visit . Inability understand trial procedure , thus inability give inform consent . History allergy sulfa drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>